Sphere Fluidics Appoints Dale Levitzke as Chief Executive Officer
April 30 2024 - 5:02AM
Business Wire
Dale Levitzke joins as Dr. Frank F. Craig,
current CEO and co-founder, announces his retirement after leading
the Company for 14 years
Sphere Fluidics, a leading provider of innovative
microfluidics-based solutions for single-cell analysis and
isolation, today announced the appointment of Dale Levitzke as CEO
with immediate effect, as Dr. Frank F. Craig, current CEO and
co-founder, announces his retirement.
Dale joins Sphere Fluidics with over 25 years’ experience in the
life science tools, biopharma, and biotechnology industries, where
he has built a strong track record in successfully driving
innovation, commercial growth, and IPO strategies. In his role as
CEO, Dale will shape Sphere Fluidics’ future commercial business
and progress the Company’s continued global expansion strategy to
reach new customers and create value for shareholders.
Throughout his career, Dale has focused on supporting
early-stage and VC-backed pioneering tools companies and steering
them towards global market success. Before joining Sphere Fluidics,
he was Senior VP of Global Sales and Support at Vizgen and in this
role established a global commercial infrastructure and rapidly
scaled the Company’s operations. Prior to this, as VP Worldwide
Sales and Marketing at Dropworks Inc., Dale’s contributions were
instrumental in developing an integrated Digital Droplet PCR
platform, and his strategic leadership culminated in the Company's
acquisition by Bio-Rad for $125 million. He has also held key
senior positions leading commercial expansion at NanoString
Technologies, Illumina Inc., and Helixis Inc. Dale holds a BSc
(Hons) in Molecular Biology and Genetics from La Trobe University
in Melbourne, Australia.
Dr. Frank F. Craig co-founded Sphere Fluidics, alongside
Professor Chris Abell and Professor Wilhelm Huck, before becoming
CEO in 2010. In this time, he has led the commercialization of
novel products and R&D services that leverage the Company’s
proprietary picodroplet technology, and uniquely established it
within the life science tools industry to address a growing
portfolio of markets, including biologics discovery, cell therapy
and synthetic biology. Sphere Fluidics has a proven track record of
over 400 international customers, including collaborations with
seven of the world’s Top 10 pharma companies, over £40 million in
investment (from prestigious angel and VC funds), and a portfolio
of 135 international patents. The Company has been well positioned
to drive this next phase of commercial development forward.
Dale Levitzke, incoming CEO, Sphere Fluidics, added:
“Sphere Fluidics’ picodroplet technology and microfluidics
platforms are transforming single cell analysis and isolation
capabilities, bringing new possibilities to biopharmaceutical
research and development. I’d like to thank Frank for his
commitment to growing a company that prides itself on delivering
high-quality products and services to its customers. I look forward
to joining the team to continue to lead and drive its ambitious
plans for commercial growth, international expansion, and eventual
exit.”
Dr. Frank F. Craig, departing CEO, Sphere Fluidics,
commented: “It has been a privilege to serve as CEO of Sphere
Fluidics for over 14 years and I am delighted to pass the baton
onto Dale as he takes over as CEO. His experience of driving
innovation and commercial success will be pivotal to advancing
Sphere Fluidics’ ambitious strategic vision and plans for
commercial growth.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430696915/en/
For further information please contact: Zyme
Communications Lily Jeffery Tel: +44 (0)7891 477 378 Email:
lily.jeffery@zymecommunications.com